Pharmacotherapy of substance use disorders in the neuroscience-based nomenclature (NbN)

Zohar, 2015, A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature, Eur Neuropsychopharmacol, 25, 2318, 10.1016/j.euroneuro.2015.08.019 Bordet, 2019, 2 Zohar, 2014, A proposal for an updated neuropsychopharmacological nomenclature, Eur Neuropsychopharmacol, 24, 1005, 10.1016/j.euroneuro.2013.08.004 Nutt, 2016, Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology, J Psychopharmacol, 30, 413, 10.1177/0269881116642903 Shen, 2018, Anticraving therapy for alcohol use disorder: a clinical review, Neuropsychopharmacol Rep, 38, 105, 10.1002/npr2.12028 Fareed, 2010, Heroin anticraving medications: a systematic review, Am J Drug Alcohol Abuse, 36, 332, 10.3109/00952990.2010.505991 Picciotto, 2012, Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior, Neuron, 76, 116, 10.1016/j.neuron.2012.08.036 Van der Zee, 2011, Acetylcholine: future research and perspectives, Behav Brain Res, 221, 583, 10.1016/j.bbr.2011.01.050 Stolerman, 1991, Behavioural pharmacology of nicotine: multiple mechanisms, Br J Addict, 86, 533, 10.1111/j.1360-0443.1991.tb01803.x Papke, 2020, Cholinergic receptors and addiction, Curr Top Behav Neurosci, 45, 123, 10.1007/7854_2020_139 Lindson, 2019, Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation, Cochrane Database Syst Rev, 4, CD013308 Fiore, 1992, Tobacco dependence and the nicotine patch. Clinical guidelines for effective use, JAMA, 268, 2687, 10.1001/jama.1992.03490190087036 Cahill, 2013, Pharmacological interventions for smoking cessation: an overview and network meta-analysis, Cochrane Database Syst Rev, 5, CD009329 Claire, 2020, Pharmacological interventions for promoting smoking cessation during pregnancy, Cochrane Database Syst Rev, 3, CD010078 Czoli, 2017, How do consumers perceive differences in risk across nicotine products? A review of relative risk perceptions across smokeless tobacco, e-cigarettes, nicotine replacement therapy and combustible cigarettes, Tob Control, 26, e49, 10.1136/tobaccocontrol-2016-053060 Tonstad, 2020, Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations, Curr Med Res Opin, 36, 713, 10.1080/03007995.2020.1729708 West, 2008, Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt, Psychopharmacology (Berl), 197, 371, 10.1007/s00213-007-1041-3 Haute Autorité de Santé, 2016, 1 Allen, 2020, GABA receptor. 2020 Jul 26, 1 Rolland, 2016, Pharmacotherapy for alcohol dependence: The 2015 recommendations of the French Alcohol Society, issued in partnership with the European Federation of Addiction Societies, CNS Neurosci Ther, 22, 25, 10.1111/cns.12489 Chick, 2012, Substitution therapy for alcoholism: time for a reappraisal?, J Psychopharmacol Oxf Engl, 26, 205, 10.1177/0269881111408463 Simioni, 2017, Thirty- versus ten-day diazepam treatment for alcohol detoxification and a comparison of drinking patterns, craving, and anxiety for up to 12 weeks: a “proof-of-concept” open-label randomized controlled trial, J Clin Psychopharmacol, 37, 722, 10.1097/JCP.0000000000000786 Agabio, 2018, Baclofen for the treatment of alcohol use disorder: the Cagliari Statement, Lancet Psychiatry, 5, 957, 10.1016/S2215-0366(18)30303-1 Rolland, 2020, France grants an approval to baclofen for alcohol dependence, Alcohol Alcohol Oxf Oxfs, 55, 44, 10.1093/alcalc/agz082 de Beaurepaire, 2019, The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective, Front Psychiatry, 9, 708, 10.3389/fpsyt.2018.00708 Rolland, 2018, Safety challenges of using high dose baclofen for alcohol use disorder: a focused review, Front Psychiatry, 9, 367, 10.3389/fpsyt.2018.00367 Auffret, 2017, Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France, Drug Saf, 40, 257, 10.1007/s40264-016-0489-7 Rolland, 2012, A case of de novo seizures following a probable interaction of high-dose baclofen with alcohol, Alcohol Alcohol Oxf Oxfs, 47, 577, 10.1093/alcalc/ags076 Anand, 2018, Multifunctional opioid ligands, Handb Exp Pharmacol, 247, 21, 10.1007/164_2018_104 Hipólito, 2008, Shell/core differences in mu- and delta-opioid receptor modulation of dopamine efflux in nucleus accumbens, Neuropharmacology, 55, 183, 10.1016/j.neuropharm.2008.05.012 Robble, 2020, Learned avoidance requires VTA KOR-mediated reductions in dopamine, Neuropharmacology, 167, 107996, 10.1016/j.neuropharm.2020.107996 Jarvis, 2018, Extended-release injectable naltrexone for opioid use disorder: a systematic review, Addict Abingdon Engl, 113, 1188, 10.1111/add.14180 Jahagirdar, 2017, 1 Lee, 2016, Extended-release naltrexone to prevent opioid relapse in criminal justice offenders, N Engl J Med, 374, 1232, 10.1056/NEJMoa1505409 Substance Abuse, 2014, 1 Lobmaier, 2011, Naltrexone depot formulations for opioid and alcohol dependence: a systematic review, CNS Neurosci Ther, 17, 629, 10.1111/j.1755-5949.2010.00194.x Maisel, 2013, Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?, Addict Abingdon Engl, 108, 275, 10.1111/j.1360-0443.2012.04054.x Mann, 2016, Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy, Eur Neuropsychopharmacol, 26, 1941, 10.1016/j.euroneuro.2016.10.008 Palpacuer, 2018, Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate, Addict Abingdon Engl, 113, 220, 10.1111/add.13974 Vorspan, 2019, What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine, Expert Opin Drug Deliv, 16, 907, 10.1080/17425247.2019.1649252 Bell, 2020, Medication treatment of opioid use disorder, Biol Psychiatry, 87, 82, 10.1016/j.biopsych.2019.06.020 Strang, 2020, Opioid use disorder, Nat Rev Dis Primer, 6, 3, 10.1038/s41572-019-0137-5 Coe, 2019, Buprenorphine pharmacology review: update on transmucosal and long-acting formulations, J Addict Med, 13, 93, 10.1097/ADM.0000000000000457 Dematteis, 2017, Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus, Expert Opin Pharmacother, 18, 1987, 10.1080/14656566.2017.1409722 Yokell, 2011, Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review, Curr Drug Abuse Rev, 4, 28, 10.2174/1874473711104010028 Chappuy, 2020, Prolonged-release buprenorphine formulations: perspectives for clinical practice, Therapie, 75, 397, 10.1016/j.therap.2020.05.007 Eder, 2005, Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy, Addiction, 100, 1101, 10.1111/j.1360-0443.2005.001128.x Beck, 2014, Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone, Addiction, 109, 617, 10.1111/add.12440 Zornoza, 2003, Pharmacology of acamprosate: an overview, CNS Drug Rev, 9, 359, 10.1111/j.1527-3458.2003.tb00260.x Kalk, 2014, The clinical pharmacology of acamprosate, Br J Clin Pharmacol, 77, 315, 10.1111/bcp.12070 Howes, 2020, Antidepressants for smoking cessation, Cochrane Database Syst Rev, 4, CD000031 Skinner, 2014, Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis, PloS One, 9, e87366, 10.1371/journal.pone.0087366 Chick, 1999, Safety issues concerning the use of disulfiram in treating alcohol dependence, Drug Saf, 20, 427, 10.2165/00002018-199920050-00003 De Ternay, 2019, Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain, Front Pharmacol, 10, 627, 10.3389/fphar.2019.00627 Koob, 2016, Neurobiology of addiction: a neurocircuitry analysis, Lancet Psychiatry, 3, 760, 10.1016/S2215-0366(16)00104-8 Aboujaoude, 2016, Naltrexone: a pan-addiction treatment?, CNS Drugs, 30, 719, 10.1007/s40263-016-0373-0 Nutt, 2015, The dopamine theory of addiction: 40 years of highs and lows, Nat Rev Neurosci, 16, 305, 10.1038/nrn3939 Allsop, 2014, Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial, JAMA Psychiatry, 71, 281, 10.1001/jamapsychiatry.2013.3947 Singh, 2016, Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials, Addiction, 111, 1337, 10.1111/add.13328 Blodgett, 2014, A meta-analysis of topiramate's effects for individuals with alcohol use disorders, Alcohol Clin Exp Res, 38, 1481, 10.1111/acer.12411 Nourredine, 2020, Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis, CNS Spectr, 3, 1, 10.1017/S1092852920001613